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Rat hypertension caused by constricting one renal artery, leaving the contra- 
lateral kidney untouched (two-kidney Goldblatt hypertension), is more char- 
acteristically accompanied by a rise in plasma renin activity than other forms of 
experimental renal hypertension (1). Also, it represents a  close counterpart of 
clinical renovascular hypertension. Thus, it is of particular importance in in- 
vestigating a possible role of the renin-angiotensin system in the pathogenesis of 
renal hypertension. 
In  this  model,  renin  preinhibitor  (2),  angiotensin  converting  enzyme  in- 
hibitor (3), and a specific competitive inhibitor of angiotensin II (4), have each 
been shown to reduce blood pressure, so arguing in favor of an active contribu- 
tion by angiotensin to the hypertensive state.  Conversely, studies relying on 
angiotensin II  (AII) 1 antibodies to neutralize endogenous angiotensin  (5,  6), 
have provided good evidence that the direct pressor effect of circulating angio- 
tensin is not essential for the development and maintenance  of this  type of 
hypertension. The issue thus remains unresolved. 
It has been suggested that the precursor of AII, angiotensin I (AI), may exert 
a direct but weak action on AII vascular receptors (7). In addition, recent work 
has shown that AI has a  significant central vasomotor action in the vertebral 
artery territory (8)  and  a  marked,  direct  stimulatory  effect on  the  adrenal 
medulla (9). Neither action is blocked nor even impaired by AII antibody. In 
view of these important findings, we felt that a study incorporating active im- 
munization against AI was needed to complement data based on AII immuniza- 
tion alone (5) and to provide more valid immunologic evidence from which to 
evaluate the part played by the renin-angiotensin system in renal hypertension. 
Materials and Methods 
Animals.--Female  Wistar rats weighing 240-290 g and kept on a standard laboratory diet 
were divided  into three groups and immunized  for 6-7 mo before  renal artery constriction. 
Immunization.--One group of 10 rats was immunized against AII by i p. injection,  at 3-wk 
* Supported by Grant G759-747 from the National Heart Foundation of Australia. 
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intervals, of  (Ash 1, ValZ)-angiotensin II (Hypertensin, Ciba Pharmaceutical Co.,  Summit, 
N. J.; 0.5 mg per rat) coupled to bovine serum albumin by glutaraldehyde condensation (10), 
and emulsified in Freund's complete adjuvant. A second group of 30 rats was similarly im- 
munized against both AI and AII with  (IleS)-angiotensin I  (Schwarz  Bio Research,  Inc., 
Orangeburg, N. Y.), and (Asn 1, ValS)-angiotensin II (0.2 mg of each peptide per rat). A con- 
trol group of 30 rats was mock immunized with Freund's adjuvant according to the same time 
schedule. 
Immunologic Evaluation.- 
Antibody  titers:  Blood from each rat was sampled at 2-3-wk intervals. A  leg vein was 
pierced  under ether anesthesia, and blood  collected  by capillarity into a  hematocrit tube 
containing EDTA  (1  mg/ml).  Serially diluted plasma  (50/zl)  was  incubated with 40 pg 
(10,000 cpm) of [I~SI]AII, or with the same amount of [IzSI]AI, at pH 7.4 and 4°C for 24 h, 
and the titer that bound 50% of each iodinated peptide was determined. 
Bioassay  Rats:  At the  termination of  the experiment, immune and control rats were 
anesthetized with Inactin (Promonta, Hamburg; 100 mg/kg i.p.), tracheotomized, vagoto- 
mized,  and injected i.m. with atropine sulfate  (1.5 mg/kg)  and pentolinium tartrate  (25 
mg/kg). Two polyethylene catheters (PE 10) were ineserted into the right jugular vein, and 
the right common carotid artery was catheterized (PES0)  and connected via a Statham pres- 
sure transducer  (Statham Instruments, Inc., Los Angeles,  Calif.)  to  a  Sanborn polygraph 
(Sanborn Engineering Co.,  Park Ridge, Ill.) for continuous monitoring of arterial pressure. 
Using the venous catheters, dose-response curves were determined for AI and AII, and pressor 
responses to hog renin (General Bioehemieals  Div., Chagrin Falls, Ohio;  1 dog U/rag) and 
norepinephrine (Levophed,  Winthrop Pharmaceuticals, New York) were recorded. 
Induction of Renovascular Itypertension.--Under  ether anesthesia, a silver clip was applied 
to the left renal artery of each immune and control rat (I1), the contralateral kidney being 
untouched. This method, used in our laboratory in previous studies involving 120 rats, has 
consistently produced hypertension in 50%  of rats,  the mean postoperative systolic blood 
pressure of these being 165 -4- 9 (SE) mm Hg, as opposed to 125 -4- 1 preoperatively. The clips 
used in our work (0.27 mm i.d.) were wider than those (0.20 mm i.d.)  recently reported to in- 
duce more predictable hypertension (5, 12). 
Blood Pressure Determination.--The  systolic blood pressure of each rat was measured twice 
a week for 3 wk before and 6 wk niter renal artery constriction, by the method of Eide, (5), 
employing a photoelectric cell and a proximal cuff on the tail of the conscious, prewarmed rat. 
RESULTS 
After 7 mo of immunization, 27 of the rats immunized against AI and All, 
and all I0 of those immunized against AII  only, were considered to be immune 
on the basis of sustained antibody titers. This was subsequently confirmed by 
bioassay. Those immunized against equal parts of AI and All were found to 
have developed antibodies with antiangiotensin titers 6-15 times greater for AI 
than for AII and were  thus predominantly AI-immune. There were  29 rats in 
the mock-immunized control group. 
Blood pressures of all rats were measured twice per week for 3 wk before renal 
artery constriction. The mean preoperative systolic blood pressure  of  the con- 
trol group was 125 4- 1 (SE), that of the (AI +  AII)-immune group was  126 4- 
1, and that of the AII-immune group 125 4- 2. Thus, sustained AI and/or AII 
immunity did not alter blood pressure (P >0.4 in each case). 
Development of ttypertension.--From  the control group of 29 rats,  14  (48%) 
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of  the  renal  artery  clip.  Corresponding  figures for  the  (AI  -1-  AII)-immune 
group were  14 out of 27  (52%),  and for the AII-immune group,  6  out of 10 
(60%). The mean systolic blood pressure of those developing hypertension in 
each group is plotted  against  time in  Fig.  1.  All  groups reached  comparable 
levels of hypertension, mean blood pressures during the period of study, from 
day 17 to 6 wk after operation, being 165 4- 4 (SE) for control rats, 167 4- 6 for 
the  (AI -t-  AII)-immune rats,  and  167  4-  9  for the AII-immune rats.  Thus, 
neither  AII  immunity,  nor  combined  AI  and  AII  immunity,  changed  the 
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FIo.  1.  Preoperative and  postoperative  systolic blood pressures of  14  control mock- 
immunized rats (•), 14 (angiotensin I +  II)-immune rats (0), and 6 angiotensin II-immune 
rats (X) that became hypertensive after left renal artery constriction. Vertical bars indicate 
standard errors of means. 
severity of hypertension from that observed in the control  group (P >  0.8  for 
each). The mean postoperative systolic blood pressure of rats failing to develop 
hypertension was 131  -4-  1 (SE)  in the control group,  129  -4-  1 in the  (AI q- 
AII)-immune group, and 132 -4- 3 in the AIl-immune group. 
Despite the fact that half of the rats in each group did not exhibit hyperten- 
sion (> 150 mm Hg) during the 6 wk after left renal artery constriction, post- 
mortem examination revealed the left kidney to be reduced in size and the right 
kidney  hypertrophied.  From  the  29  nonimmune  control  rats,  those  that  de- 
veloped hypertension had a  ratio of left kidney weight:right kidney weight of 
0.51  -4- 0.08  (SE),  and those failing to become hypertensive 0.59 -4- 0.08. The 
last two groups were not significantly different from each other (P >  0.4), but 
both were highly significantly different from the ratio of 0.99  -4- 0.01  found in 242  RENAL  HYPERTENSION  IN  ANGIOTENSIN-IMMUNE  RATS 
normal unoperated female rats of the same age (P <  0.001 in each case). In the 
angiotensin-immune groups, the hypertensive rats had a left: right kidney weight 
ratio of 0.56  -4-  0.08,  and those failing to become hypertensive, 0.60  :i:  0.09 
(differences from corresponding nonimmune groups, P  >  0.6). As in the control 
group, this difference was not significant (P >  0.7). 
Immunologic Evaluat~on.--The  efficacy of  angiotensin  immunization  was 
tested in two ways: (a) by regularly sampling the blood of all rats, throughout 
the period of study, for in vitro radioimmunological determination of plasma 
antibody concentration, expressed as antibody titer; and (b)  by injecting the 
rats i.v. with angiotensin, renin, and norepinephrine, to determine in vivo their 
pressor sensitivity to synthetic and endogenous angiotensin. 
(a) In the group of rats immunized against both angiotensin I  and II, the 
mean plasma anti-AI titer before renal artery constriction was 1/~9,ooo -4- ~,ooo 
(SE), and the anfi-AII titer 1~,ooo :t: 1/~o  0. Immunization was continued every 
2-3 wk postoperatively, so that titers remained fairly constant. The mean val- 
ues for this group over the entire postoperative period were: anti-AI antibody 
~5,ooo :h  ~,6oo  and anti-All ~,0o0  :i: 1/~,ooo. In the case of the AII im- 
munized  group,  the  mean  anti-AII  titer  for  the  postoperative  period  was 
~8,oo0 :t: ~,ooo, but titers waned between immunizations to values as low as 
1~,oo o :t: 1/~o  o. No AI cross-reactivity was detectable. High titers of antibody 
against AII were more difficult to elicit and maintain than were those against 
AI. 
In the (AI +  AII)-immune group, during the first 17 postoperative days, the 
14 rats that developed hypertension proved to have somewhat higher antibody 
titers  than  did  the  13  remaining  normotensive.  Mean  anti-AI  titers  were 
~2,ooo ±  ~,9oo (SE) and ~7,ooo :t: 1/~,ooo for hypertensives and normoten- 
sives, respectively (0.05 <  P  <  0.1). The difference between their anti-All tit- 
ers was not significant (P >  0.2). Similarly, in the AII-immune group, during 
this period, the mean anti-AII titer of the rats that became hypertensive was 
~{8,ooo  :t:  1/~,6oo (SE),  as opposed to 1/g,ooo ±  1/~,7oo in  those remaining 
(0.05  <  P  <  o.1). 
In Fig. 2, the maximal postoperative systolic blood pressure of each (A1 + 
AII)-immunized rat  that  became hypertensive is plotted  against its plasma 
anti-AI antibody titer at the time of the peak pressure reading. It is evident 
that the severity of hypertension was virtually uninfluenced by anti-AI anti- 
bodies (correlation coefficient =  0.17). 
(b) Table I summarizes the pressor sensitivity of angiotensin-immunized and 
control mock-immunized rats to i.v. injected AI, AII, hog renin,  and norepi- 
nephrine. Six  hypertensive rats  from each group (classed  as nonimmune, pre- 
dominantly AI-immune, and AII-immune, on the basis of their antibody titers) 
were set up as bioassay preparations to test in vivo the degree and specificity of 
their immunity. Six nonimmune rats that did not become hypertensive were 
also included. A 3--4-point log dose-response plot was first determined for both OATES,  STOKES~  STOREY~  GLOVER~ AND  SNOW  243 
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FIG. 2.  The maximal systolic blood pressures of 14 predominantly AI-immune rats (open 
circles) that became hypertensive after unilateral renal artery constriction, are plotted against 
their anti-AI antibody titers at the times of peak pressure. Note the lack of correlation. The 
mean of the maximal pressures in the control group (closed circle) was 183 mm Hg (q-2 SD 
indicated by vertical bars), as compared to 185 in the immune group. 
AI and AII, and the doses required to give a systemic pressor response of 15 
mm Hg were calculated by solving the linear regression equations. Pressure in- 
crements resulting from paired injections of 0.05 U  of hog renin, and 30 ng of 
norepinephrine were then recorded. 
From examination of Table I, it is clear that, for nonimmune clipped rats, 
there was no significant difference between those that were normotensive, and 
those  that  were hypertensive, with  respect to  responsiveness to  the  pressor 
agents tested (P >  0.3 in each case). On the other hand, much greater doses of 
AI and All were required to elicit a pressure rise of 15 mm Hg in each of the 
angiotensin-immunized groups than in control rats with hypertension of com- 
parable severity. In addition, the pressor response to 0.05 U of hog-renin, averag- 
ing 40.8 -4- 3.2 (SE) mm Hg in the nonimmune hypertensive rats, was virtually 
abolished in both the predominantly AI-immune and  the All-immune groups 
(P <  0.001), despite the fact that the mean antibody titers of both groups were 
considerably lower at the time of bioassay than they had been during the crucial 
period of developing hypertension (60 % and 44 %, respectively). The response 
to 30  ng  of norepinephrine was  not  significantly different in  either immune 
group from that seen in the nonimmune hypertensive rats (P >  0.2 for each). 
The predominantly AI-immune group (Table I, column 3) was found to be 
more resistant to the pressor effects of both endogenous angiotensin, liberated 
by injected renin,  and  synthetic  (IleS)-angiotensin I,  than  was  the  All  im- 
munized group (column 4),  as may have been anticipated from the differing 
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TABLE  I 
Pressor Sensitivity of Hypertensive, Angiotensin-Immune  Rats,* Compared to that of 
Normotensive and Hyperlenslve, Nonimmune  Rats* (Means -4- SE) 
Normotensive nonimmune  Hypertensive  Hypertensive AI-immune  Hypertensive AII-immune  nonlmmune 
Blood pressure (BP) 
(mm Hg) 
135  4-  2  171  4-  7  172  4-  8  172  4-  10 
Angiotensin dose (rig 
i.v.) causing 15 mm 
Hg BP rise 
AI  2.8  -¢- 0.2  2.9  ~  0.3  754  4-  252  223  4-  110 
AII  2.5  -¢- 0.2  2.5  q- 0.3  102  4-  42  411  -¢-  245 
BP response to 0.05 
units of hog renin 
(mm Hg) 
45  4-4 
BP response to 30 ng of 
norepinephrine (ram 
Hg) 
334-1 
41  -¢- 3  1.7  4-  0.9  4.2  4-  1.2 
(Negligible) 
33  -¢- 3  29  4-  2  28  +  3 
Plasma antiangiotensin 
antibody titers at the 
time of bioassay 
AI  Nil  Nil  1/19,000  4-  1/4,900  Nil 
AII  Nil  Nil  1/1,000  4-  1/300  1/8,000  -4-  1/1,600 
* Six rats from each of the four groups were studied 6-8 wk after renal artery constriction, 
and had  been classed as nonimmune, predominantly  AI-immune, or AII-immune, on the 
basis of plasma antibody titers  against  (Ile6)-angiotensin I  (AI), and (Asn  1,  Val6)-angio- 
tensin II (AII), determined by radioimmunoassay. 
DISCUSSION 
It is reasonable to suppose that, if pressor activity of angiotensin were pri- 
marily involved in the  etiology of renovascular hypertension caused by uni- 
lateral renal artery constriction, then effective immunization  against angioten- 
sin should prevent such hypertension (5,  13). It has been demonstrated that, 
only 3  wk  after  induction of  unilateral renal ischemia,  the  ischemic kidney 
ceases  to  release  into  renal vein blood  the  potent vasopressor agent demon- 
strable in arterial blood during the acute stage of hypertension (14). It is possi- 
ble that hypertension may then persist independent of the causative agent (11). 
Thus,  in  the  present study,  as  in the  AH  immunization study of  Eide  (5), 
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clip, and antiangiotensin antibody titers of the rats were maintained at peak 
levels postoperatively, thoughout the early stage of the hypertension. 
To test in vivo the adequacy of their immunity, angiotensin-immunized and 
mock-immunized control rats were challenged with large doses of AI, AII, and 
hog renin. None of the rats in either the predominantly Ai-immune group or the 
AII-immune group responded at all to doses of M  or AII less than 55 ng, which 
was about 50 times the dose required to give a detectable pressor response in 
nonimmune rats with hypertension of comparable severity. One hypertensive 
rat with an anti-AI antibody titer of 1/~5,000 at the time of bioassay (as com- 
pared to the mean titer of 1/~2,000 attained by the 14 AI-immune rats that be- 
came hypertensive), required 2,100 ng of AI to elicit a pressor response. Thus, 
despite the fact that antibody titers had fallen considerably by the time of bio- 
assay, our rats (summarized in Table I), were at least as effectively immune as 
were those of Eide (5), which required an average angiotensin dose of 490 ng to 
produce a definite pressor effect. The lack of responsiveness of the immune ani- 
mals was not due to a  nonspecific refractoriness, because they all responded 
normally to norepinephrine. Furthermore, the injection of hog renin ensured 
that the antibodies raised by immunization of the rats against synthetic angio- 
tensins I  and II were also able to neutralize endogenous angiotensin liberated 
from rat renin substrate by the injected renin. 
For several reasons, listed below, it occurred to us that AII immunization 
might not completely block endogenous activity of the renin-angiotensin sys- 
tem. We therefore felt that it would be important to try combined AI and AII 
immunization before ruling out, on the basis of immunological evidence, par- 
ticipation of a direct pressor effect of circulating angiotensin in renal hyperten- 
sion. The following recent findings cast doubt upon the adequacy of All immu- 
nization alone: (a) The catecholamine-releasing effect of AII is blocked by AII 
antibody, whereas adrenal medullary responses to AI remain unchanged (9). (b) 
The hypertensive effect of vertebral artery infusion of AI in dogs is virtually 
unimpaired by administration of AII antibody, while that of AII is abolished 
(8). (c) AI may have direct activity on AII receptors amounting to 4 % of that 
of AII (7), and, in addition, may be partly converted to AII, intramurally, at 
extrapulmonary sites (7),  thus minimizing exposure of AII to circulating anti- 
bodies. (d)  Concentrations of AI in renal venous blood are reported to be 45 
times greater than those of AII and in arterial blood, 24 times greater (15). The 
circulating concentration of AI, relative to that of AII, thus appears to be high 
enough to consider AI as an effector hormone (15). 
From examination of Table I, it is clear that rats, shown in vitro to have pro- 
duced antibodies directed predominantly against AI, inactivated AI in vivo 
more effectively than they did AII. On the other hand, rats immunized against 
AII inactivated injected AI less readily than they did AII, consistent with the 
in vitro specificity of their antibodies,  2 but also consistent with residual activity 
2 For immunization, antibody assay, and i.v. injection, the AI used was (IleS)-angiotensin 
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of AI, as mentioned above (a-c). It should be pointed out that the anti-AII titers 
of the group immunized against AI and All were four times greater during the 
time of developing hypertension than they were at the time of bioassay, so that 
this group was indeed effectively immune to both AI and All. Results reported 
here thus establish that sustained immunity to both AI and All neither changes 
the preoperative blood pressure of rats from that of control mock-immunized 
rats nor alters the incidence or severity of hypertension induced by unilateral 
renal artery constriction. 
There is much evidence indicative of increased reactivity of blood vessels to 
norepinephrine and angiotensin in hypertensive animals (16,  17) and man (18, 
19).  The pressor effect of small quantities of free endogenous angiotensin, es- 
caping neutralization by circulating antibodies, could be increased by such aug- 
mented vascular reactivity. Thus, it was of interest to note that, in the present 
study, there was no significant difference between normotensive rats and hyper- 
tensive  rats  (whether  angiotensin  immune  or  nonimmune),  with  respect  to 
pressor sensitivity to norepinephrine. Nor was there any significant difference 
between the pressor responsiveness of normotensive and  hypertensive nonim- 
mune rats, to angiotensins I  and II. This is in contrast to results of Christlieb 
et al.  (20),  who found that rats made hypertensive by unilateral renal artery 
clipping showed a  significantly subnormal responsiveness to angiotensin. Per- 
haps the explanation for the differing results lies in the fact that our control 
rats had been subjected to renal artery constriction, but had not become hyper- 
tensive, whereas, in the study of Christlieb, normal rats served as controls. Our 
rats were also ganglion blocked before bioassay to minimize interference fl'om 
homeostatic blood pressure control mechanisms. 
The evidence from our experiments thus makes it extremely difficult to sus- 
tain any major role for circulating AI, or AII, in initiating that form of reno- 
vascular hypertension induced in rats by unilateral  renal  artery constriction 
without contralateral nephrectomy. The results in no way conflict with those of 
Carretero et al.  (21), for these authors  studied  the  accelerated or malignant 
phase of hypertension produced in rats by coarctation of the aorta. Our results 
also rule out involvement of AII produced from circulating AI by conversion 
within arteriolar walls, close to receptor sites (7, 22), for AI immunity would 
block such a mechanism where AII immunity might fail. Moreover, although 
the renin-angiotensin system has been shown to possess sufficient time response 
and gain characteristics to participate significantly in the normal regulation of 
arterial pressure  (23), it is  clear that a  normal pressure is maintained in the 
conscious rat, despite sustained immunity to both forms of angiotensin. 
SUMMARY 
Rats,  actively immunized  against  angiotensin  I  (AI)  and  angiotensin  II 
(All),  were  subjected  to  unilateral  renal  artery  constriction  to  determine 
whether the resulting hypertension, which may still  ensue in the animal im- 
munized against All, could be prevented by such combined immunity. OATES, STOKES, STOREY, GLOVER, AND  SNOW  247 
Sustained immunity to both AI and AII neither changed preoperative blood 
pressures of the rats from those of control mock-immunized rats nor altered the 
incidence or severity of renal clip hypertension. Vascular hyperresponsiveness 
to small quantities of free angiotensin could not be invoked to explain the hyper- 
tension, for there was no significant difference between mock-immunized hyper- 
tensive animals, and those remaining normotensive, regarding pressor sensitivity 
to  intravenous  M,  AII, renin,  and  norepinephrine.  (AI +  AII)-immunized 
hypertensive  rats  required  AI  doses  averaging 260  times  greater  than  non- 
immune hypertensives to elicit equipressor responses,  and  were refractory to 
renin, but not to norepinephrine. 
Thus,  while previous studies have not excluded direct participation  of en- 
dogenous M  in renal clip hypertension in rats, evidence from our experiments 
makes it extremely difficult to sustain  any pressor function  therein for circu- 
lating AI or AII. Our results also preclude involvement of AII produced from 
circulating AI by conversion within arteriolar walls, close to receptor sites, since 
AI immunity would block this mechanism of action. 
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